UDK: 617.52-089:616.716.1/4-002.4

BISPHOSPHONATE-RELATED OSTEONECROSIS OF THE JAW

BISPHOSPHONATE-RELATED OSTEONECROSIS OF THE JAW

1ФГБОУ ВО «Волгоградский государственный медицинский университет» Министерства здравоохранения Российской Федерации, кафедра хирургической стоматологии и ЧЛХ; 2ФГБОУ ВО «Астраханский государственный медицинский университет» Министерства здравоохранения Ро

Abstract

Bisphosphonates (BPs) are a class of drug used to treat osteoporosis and malignant bone metastasis. BPs show high binding capacity to the bone matrix, especially in sites of active bone metabolism. According to modern data, bisphosphonate osteonecrosis of the jaws (BPONJ) is a complication of antiresorptive therapy, characterized by death and exposure of the bone area, which persists for more than 8 weeks, with subsequent progression of the process, provided there is no radiation therapy on the head area in history. BRONJ can adversely affect quality of life, as it may produce significant morbidity. The purpose of this article is to offer a perspective on how dentists should manage patients on BPs, and to present diagnostic aids and treatment s strategies to the condition.

Keywords

Bisphosphonates, osteonecrosis, bisphosphonate associated osteonecrosis, low markedness inflammation, lower jaw.

Contacts

Фомичев Евгений Валентинович – д. м. н., профессор, зав. кафедрой хирургической стоматологии и ЧЛХ, ВолгГМУ, e-mail: f3vstom@yandex.ru